ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 66 filers reported holding ONCOCYTE CORP in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $60,272 | +58.6% | 262,052 | +400.5% | 0.00% | – |
| Q3 2022 | $38,000 | -87.0% | 52,354 | -83.9% | 0.00% | – |
| Q2 2022 | $293,000 | +41.5% | 325,517 | +133.9% | 0.00% | – |
| Q1 2022 | $207,000 | -55.1% | 139,160 | -34.6% | 0.00% | – |
| Q4 2021 | $461,000 | -44.5% | 212,668 | -8.7% | 0.00% | – |
| Q3 2021 | $830,000 | -42.8% | 233,004 | -7.9% | 0.00% | – |
| Q2 2021 | $1,451,000 | -24.3% | 252,945 | -31.5% | 0.00% | – |
| Q1 2021 | $1,916,000 | +262.9% | 369,221 | +67.0% | 0.00% | – |
| Q4 2020 | $528,000 | +1100.0% | 221,144 | +599.2% | 0.00% | – |
| Q3 2020 | $44,000 | -35.3% | 31,627 | -11.2% | 0.00% | – |
| Q2 2020 | $68,000 | +21.4% | 35,627 | +57.3% | 0.00% | – |
| Q1 2020 | $56,000 | +47.4% | 22,656 | +49.6% | 0.00% | – |
| Q2 2019 | $38,000 | +2.7% | 15,145 | -14.8% | 0.00% | – |
| Q1 2018 | $37,000 | – | 17,771 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 17,349,945 | $25,851,000 | 1.86% |
| Defender Capital, LLC. | 2,562,130 | $4,001,000 | 1.39% |
| PURA VIDA INVESTMENTS, LLC | 12,223,953 | $18,214,000 | 0.59% |
| Penbrook Management LLC | 578,150 | $861,000 | 0.56% |
| ACT CAPITAL MANAGEMENT, LLC | 330,000 | $492,000 | 0.52% |
| Orbimed Advisors | 3,493,800 | $5,206,000 | 0.08% |
| CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $112,000 | 0.07% |
| Fort Sheridan Advisors LLC | 135,000 | $201,000 | 0.06% |
| AWM Investment Company, Inc. | 241,867 | $360,000 | 0.05% |
| WEALTH EFFECTS LLC | 49,000 | $73,000 | 0.03% |